Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems

Rosar, Florian; Bohnenberger, H; Moon, Euy Sung; Rösch, Frank; Denig, A.; Vincenz-Zörner, D; Hoffmann, Manuela Andrea; Khreish, Fadi; Ezziddin, Samer; Schreckenberger, Mathias; Buchholz, Hans‐Georg; Schaefer-Schuler, Andrea

doi:10.1016/j.apradiso.2021.109599

Cited by 6 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the dose calibrators, Lima et al [7] used a similar approach of defining local calibration factors based on a linearity method for scandium-44. The authors also compared their measurements to other quantitative approaches found in the literature ( [3,6,16], which assumed the scandium-44 measurement as a product of the measurement taken with the fluorine-18 setting multiplied by a factor (0.8). In this study, this linearity method was utilized, along with a vendor-technetium-99m reference-based method and, as per Lima et al [7], it was compared with the fluorine-18-setting method.…”

Section: Discussionmentioning

confidence: 99%

“…The latest software version only allowed the scale to be either 1.0 or 0.5. Based on the factor used for fluorine-18 measurement and multiplying it by 0.8 [3,6], a difference of 40% was obtained. The linearity method and the vendor-technetium-99m reference-based method indicated lower differences and, as a result, were chosen for all subsequent activity dispensing.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Previous work with scandium-44 showed the capability of clinical systems to deal with non-pure emission radioisotopes provided the appropriate corrections were applied [6,7]. Despite the promising results obtained with scandium-44 [6,7], the emission of high-energy γ-radiation (Eγ = 1157 keV) may be considered a drawback. This opens the discussion of whether another radioisotope from the Sc family, namely scandium-43, with similar physical characteristics but without the emission of high-energy γ-rays, would be more suitable for clinical applications.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides

et al. 2021

View full text Add to dashboard Cite

Scandium-44 has been proposed as a valuable radionuclide for Positron Emission Tomography (PET). Recently, scandium-43 was introduced as a more favorable option, as it does not emit high-energy γ-radiation; however, its currently employed production method results in a mixture of scandium-43 and scandium-44. The interest in new radionuclides for diagnostic nuclear medicine critically depends on the option for image-based quantification. We aimed to evaluate and compare the quantitative capabilities of scandium-43/scandium-44 in a commercial PET/CT device with respect to more conventional clinical radionuclides (fluorine-18 and gallium-68). With this purpose, we characterized and compared quantitative PET data from a mixture of scandium-43/scandium-44 (~68% scandium-43), scandium-44, fluorine-18 and gallium-68, respectively. A NEMA image-quality phantom was filled with the different radionuclides using clinical-relevant lesion-to-background activity concentration ratios; images were acquired in a Siemens Biograph Vision PET/CT. Quantitative accuracy with scandium-43/scandium-44 in the phantom’s background was within 9%, which is in agreement with fluorine-18-based PET standards. Coefficient of variance (COV) was 6.32% and signal recovery in the lesions provided RCmax (recovery coefficient) values of 0.66, 0.90, 1.03, 1.04, 1.12 and 1.11 for lesions of 10-, 13-, 17-, 22-, 28- and 37-mm diameter, respectively. These results are in agreement with EARL reference values for fluorine-18 PET. The results in this work showed that accurate quantitative scandium-43/44 PET/CT is achievable in commercial devices. This may promote the future introduction of scandium-43/44-labelled radiopharmaceuticals into clinical use.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although 68 Ga or 44 Sc can be produced in a cyclotron [75][76][77][78], they can advantageously be produced in a cyclotron-independent manner [79][80][81]. These radionuclides can be produced in a commercially available 68 Ge/ 68 Ga or 44 Ti/ 44 Sc generator, a result more affordable and accessible to any PET center [79][80][81]. 44 Sc presents further advantages allowing multiplexed PET (mPET) imaging.…”

Section: Selection Of An Adequate Radionuclide That Fits With the Eng...mentioning

confidence: 99%

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Ruiz-López

Calatayud-Pérez

Castells-Yus

et al. 2021

Cancers

View full text Add to dashboard Cite

Neuroimaging has transformed neuro-oncology and the way that glioblastoma is diagnosed and treated. Magnetic Resonance Imaging (MRI) is the most widely used non-invasive technique in the primary diagnosis of glioblastoma. Although MRI provides very powerful anatomical information, it has proven to be of limited value for diagnosing glioblastomas in some situations. The final diagnosis requires a brain biopsy that may not depict the high intratumoral heterogeneity present in this tumor type. The revolution in “cancer-omics” is transforming the molecular classification of gliomas. However, many of the clinically relevant alterations revealed by these studies have not yet been integrated into the clinical management of patients, in part due to the lack of non-invasive biomarker-based imaging tools. An innovative option for biomarker identification in vivo is termed “immunotargeted imaging”. By merging the high target specificity of antibodies with the high spatial resolution, sensitivity, and quantitative capabilities of positron emission tomography (PET), “Immuno-PET” allows us to conduct the non-invasive diagnosis and monitoring of patients over time using antibody-based probes as an in vivo, integrated, quantifiable, 3D, full-body “immunohistochemistry” in patients. This review provides the state of the art of immuno-PET applications and future perspectives on this imaging approach for glioblastoma.

show abstract